血管免疫母细胞性T细胞淋巴瘤的结局与预后因素:国际T细胞项目最终报告
该研究对2006至2018年国际前瞻性T细胞项目(NCT01142674)中282例血管免疫母细胞性T细胞淋巴瘤(AITL)患者进行亚组分析,5年总生存(OS)率和无进展生存(PFS)率分别为44%和32%,首次完全缓解(CR1)后接受自体干细胞移植(ASCT)者结局改善。多因素分析确定年龄≥60岁、ECOG体能状态>2、C反应蛋白升高和β2微球蛋白升高与不良结局相关,并据此开发新预后评分(AITL评分)区分低、中、高危组,5年OS率分别为63%、54%和21%。24个月内疾病进展(POD24)是强预后因素,无POD24者5年OS率为63%,有POD24者仅6%(P < .0001)。
要点
- AITL患者5年OS率和PFS率分别为44%和32%,CR1后ASCT与结局改善相关。
- 年龄≥60岁、ECOG>2、CRP升高和β2微球蛋白升高与不良结局独立相关。
- AITL评分区分低、中、高危组,5年OS率分别为63%、54%和21%;POD24者5年OS率仅6%。
核心结论
- AITL预后差,5年OS率和PFS率分别为44%和32%,CR1后ASCT与结局改善相关。
- 基于年龄、ECOG、CRP和β2微球蛋白的新AITL评分判别力优于现有预后指数。
- POD24是强预后因素,有POD24者5年OS率仅6%。
研究设计与样本
- 国际前瞻性T细胞项目(NCT01142674)的亚组分析,纳入2006至2018年282例AITL患者。
主要发现
- 5年OS率和PFS率分别为44%和32%,CR1后ASCT者结局改善。
- 多因素分析显示年龄≥60岁、ECOG>2、CRP升高和β2微球蛋白升高与不良结局相关。
- AITL评分低、中、高危组5年OS率分别为63%、54%和21%,判别力优于现有预后指数。
- 无POD24者5年OS率为63%,有POD24者仅6%(P < .0001)。
关键数值与推荐
- AITL评分低危组5年OS率63%,中危组54%,高危组21%。
- 无POD24者5年OS率63%,有POD24者6%(P < .0001)。
临床怎么用
- 可将年龄、ECOG、CRP和β2微球蛋白纳入AITL预后评估,AITL评分有助于风险分层。
- POD24可作为强预后指标,CR1后ASCT可能改善适合患者的结局。
局限性
- 数据需在同质治疗的前瞻性队列中验证。
- AITL的最佳治疗仍是未满足的需求,需要新治疗方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed a subset analysis of 282 patients with AITL enrolled between 2006 and 2018 in the international prospective T-cell Project (NCT01142674). The primary and secondary end points were 5-year overall survival (OS) and progression-free survival (PFS), respectively. We analyzed the prognostic impact of clinical covariates and progression of disease within 24 months (POD24) and developed a novel prognostic score. The median age was 64 years, and 90% of patients had advanced-stage disease. Eighty-one percent received anthracycline-based regimens, and 13% underwent consolidative autologous stem cell transplant (ASCT) in first complete remission (CR1). Five-year OS and PFS estimates were 44% and 32%, respectively, with improved outcomes for patients who underwent ASCT in CR1. In multivariate analysis, age ≥60 years, Eastern Cooperative Oncology Group performance status >2, elevated C-reactive protein, and elevated β2 microglobulin were associated with inferior outcomes. A novel prognostic score (AITL score) combining these factors defined low-, intermediate-, and high-risk subgroups with 5-year OS estimates of 63%, 54%, and 21%, respectively, with greater discriminant power than established prognostic indices. Finally, POD24 was a powerful prognostic factor with 5-year OS of 63% for patients without POD24 compared with only 6% for patients with POD24 (P < .0001). These data will require validation in a prospective cohort of homogeneously treated patients. Optimal treatment of AITL continues to be an unmet need, and novel therapeutic approaches are required.
引用
- Advani RH, Skrypets T, Civallero M, et al. Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood. 2021. PMID: 34292324. doi:10.1182/blood.2020010387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。